Alkermes v. Nanjing Delova Biotech: Four-Patent Meloxicam Injection Dispute Transferred to Newark
Alkermes, PLC brought an infringement action against Chinese biotech Nanjing Delova Biotech Co., Ltd. in the District of New Jersey, asserting four U.S. patents covering meloxicam injection 30 mg/mL formulations. After 302 days, the case was transferred to the Newark division — reshaping the procedural landscape before any merits ruling.
Alkermes Pursues Meloxicam Injection IP Against Chinese Generic Entrant
On August 24, 2023, Alkermes, PLC filed suit against Nanjing Delova Biotech Co., Ltd. in the U.S. District Court for the District of New Jersey, asserting infringement of four U.S. patents — US10881663B2, US11458145B2, US10709713B2, and US9974746B2 — all directed to meloxicam injection 30 mg/mL formulations. The action is consistent with an ANDA-pathway dispute, wherein a branded pharmaceutical company challenges a generic or biosimilar applicant’s attempt to enter the market with a competing injectable meloxicam product.
On June 21, 2024 — 302 days after filing — the case was transferred to the Newark division of the same district court. An intra-district transfer of this kind does not terminate the litigation on the merits; rather, it reassigns the matter to a different judicial unit within New Jersey, typically for administrative or docket-management reasons. No verdict, claim construction ruling, or settlement terms appear in the public record at the time of transfer.
The relatively short timeline to transfer, before any substantive merits activity became public, suggests procedural posture rather than any resolution on the patent claims. What drove the specific reassignment to Newark — whether judicial workload, venue convenience, or local rules compliance — is not disclosed in the public record. The case remains live and the four asserted patents continue to carry full enforceability unless challenged or invalidated in subsequent proceedings.
Filing to Case Transferred in 302 days
302 days from filing to transfer — typical for intra-district reassignment prior to substantive proceedings
Case transferred to Newark: what the venue change means for this dispute
Intra-district transfer is procedural, not a merits ruling
A transfer to the Newark division means the case has been reassigned within the District of New Jersey — not dismissed, not decided, and not settled. The same claims, patents, and parties carry forward. Intra-district transfers typically reflect docket-management decisions, local rule compliance, or judicial availability. No substantive findings on infringement or validity have been made.
Procedural reassignment onlyAlkermes retains all four patent claims in Newark
The transfer does not disadvantage Alkermes in any substantive sense. Its infringement claims based on US10881663B2, US11458145B2, US10709713B2, and US9974746B2 remain fully intact. The Newark division is within the same federal circuit, so case law and precedent are unchanged. Alkermes must simply continue prosecution before a new docket assignment.
Claims preservedNanjing Delova faces same four-patent exposure in Newark
For Nanjing Delova Biotech, the transfer changes courtroom logistics but not legal exposure. The company still faces infringement claims across a four-patent portfolio covering meloxicam injection formulations. Any ANDA or market entry strategy must continue to account for all four asserted patents until the court rules on validity, infringement, or the parties reach resolution.
Exposure unchangedGeneric meloxicam market entry remains blocked pending resolution
Until the Newark court addresses the merits, Nanjing Delova’s path to commercialising a competing meloxicam injection 30 mg/mL product in the U.S. remains legally contested. The breadth of Alkermes’ four-patent portfolio — spanning multiple application filings — suggests layered protection that a generic entrant would need to design around or challenge through IPR or litigation defences.
Market entry still contestedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Alkermes, PLC | Company | Specialty pharmaceutical company — holder of US10881663B2 and three related meloxicam injection patentsSearch in Eureka ↗ |
| Defendant | Nanjing Delova Biotech Co., Ltd. | Company | Chinese biotech company developing injectable meloxicam formulations for the U.S. marketSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for Alkermes, PLCSearch in Eureka ↗ |
| Plaintiff counsel | Tyler Doh | Attorney | Counsel for Alkermes, PLCSearch in Eureka ↗ |
| Plaintiff counsel | VISHAL CHANDRA GUPTA | Attorney | Counsel for Alkermes, PLCSearch in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Alkermes, PLCSearch in Eureka ↗ |
| Plaintiff law firm | Steptoe, LLP | Law Firm | Representing Alkermes, PLCSearch in Eureka ↗ |
| Defendant counsel | Eric I. Abraham | Attorney | Counsel for Nanjing Delova Biotech Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Stephanie-Rose Orlando | Attorney | Counsel for Nanjing Delova Biotech Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | William Murtha | Attorney | Counsel for Nanjing Delova Biotech Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Hill Wallack LLP | Law Firm | Representing Nanjing Delova Biotech Co., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The transfer order records that the case was moved to the Newark division on June 21, 2024, with no accompanying merits ruling. This language confirms a purely administrative reassignment within the District of New Jersey. Neither party has prevailed or conceded on any patent claim. The infringement action — covering four meloxicam injection patents — continues before a new docket, leaving validity, claim scope, and any ANDA linkage to be determined in subsequent proceedings.
US10881663B2 and portfolio — meloxicam injectable formulation patents
The four asserted patents — US10881663B2, US11458145B2, US10709713B2, and US9974746B2 — form a coordinated portfolio protecting injectable meloxicam formulations at 30 mg/mL. Filed across application numbers in the US15 and US16 series, the patents span formulation composition, preparation methods, and clinical use, suggesting incremental claim layering around a core innovation. Meloxicam injection represents a non-opioid analgesic option for post-operative pain, making this technology commercially significant in a market sensitive to opioid-sparing strategies.
Alkermes’ decision to assert all four patents simultaneously against a single defendant signals confidence in portfolio depth and a strategy designed to maximise litigation leverage and deter generic market entry. The US9974746B2 patent, filed under the earlier US15/130255 application, likely anchors the priority chain. Competitors and generic manufacturers seeking to enter the injectable meloxicam space must design around or invalidate the full cluster — a substantially higher bar than contesting a single patent. IPR petitions targeting each asserted patent individually represent the most direct non-litigation pathway for challengers.
Should you run an FTO against Alkermes’ meloxicam injection patent portfolio?
Any company developing, manufacturing, or seeking U.S. regulatory approval for an injectable meloxicam product — particularly at 30 mg/mL — should treat this four-patent portfolio as a primary FTO priority. The active enforcement action against Nanjing Delova Biotech confirms Alkermes is willing to litigate against foreign generic entrants. R&D teams should assess whether their formulation, process, or dosage claims overlap with the scope of US10881663B2, US11458145B2, US10709713B2, or US9974746B2 before committing to clinical or commercial development.
PatSnap Eureka’s FTO Search Agent can map your product’s technical characteristics against each of the four asserted patents, identify claim overlap risks, and surface prior art that may support invalidation arguments. Eureka also tracks the Newark district court docket for claim construction orders that will define the enforceable scope of each patent — critical intelligence for any ANDA filer or branded competitor building a freedom-to-operate position in injectable NSAIDs.
Run a freedom-to-operate analysis on US10881663B2 to assess your product’s exposure
Run FTO in Eureka →Similar injectable pharmaceutical patent infringement cases in New Jersey
Cases involving injectable drug formulation patents asserted in the District of New Jersey against ANDA or generic entrants, including multi-patent portfolio enforcement actions.
What this case signals for the injectable pharmaceutical IP landscape
Four overlapping formulation patents and a Chinese generic entrant: this dispute reflects a widening front in branded injectable drug enforcement.
Multi-patent stacking is the standard playbook for injectable drug protection
Alkermes asserting four patents across different application numbers — all covering meloxicam injection 30 mg/mL — is consistent with a deliberate IP layering strategy. Companies developing injectable formulations should expect multi-patent clusters, not single-patent exposure, when assessing freedom to operate in this space.
ANDA-adjacent disputes increasingly target Chinese generic manufacturers
The targeting of Nanjing Delova Biotech reflects a broader trend of U.S. branded pharmaceutical companies filing infringement actions against Chinese ANDA filers or market entrants. R&D teams and in-house counsel at generic drug companies with U.S. market ambitions should map branded portfolios before filing.
Alkermes v Nanjing — key questions answered
Alkermes asserted four U.S. patents: US10881663B2, US11458145B2, US10709713B2, and US9974746B2. All four cover meloxicam injection formulations at 30 mg/mL and were filed across application numbers in the US15 and US16 series, forming a layered formulation patent portfolio.
The public record reflects only that the case was transferred to the Newark division on June 21, 2024. The specific reason — whether administrative, docket management, or local rule compliance — is not disclosed. The transfer is intra-district and does not affect the merits of the infringement claims.
As of the transfer date of June 21, 2024, the case was reassigned to the Newark division of the District of New Jersey with no merits ruling recorded. The infringement action based on all four meloxicam injection patents remains active. No settlement, verdict, or dismissal has been entered in the public record.
The dispute centres on meloxicam injection at 30 mg/mL, a non-opioid injectable analgesic used for post-operative pain management. Alkermes holds a branded position in this product category and is asserting its formulation patent portfolio to challenge Nanjing Delova Biotech’s competing product development or regulatory filing.
Inter partes review (IPR) at the USPTO is a viable pathway for Nanjing Delova Biotech to challenge the validity of each of the four asserted patents independently of the district court proceedings. IPR petitions must typically be filed within one year of service of a complaint. Given the August 2023 filing date, the IPR window for some or all asserted patents may be approaching or may have passed, depending on service date — practitioners should verify timing carefully.
PatSnap Eureka searches patents and litigation data to answer instantly.